Efficient low-concentration phosphate removal from sub-healthy surface water by adsorbent prepared based on functional complementary strategy.

The remediation of low-concentration phosphorus polluted surface water (LP-SW) is one of most challenging environmental issues worldwide. Adsorption is more suitable for LP-SW remediation due to its low cost and operability. Based on the strategy of functional complementation among industrial solid wastes (ISWs), ISW-based phosphate absorbent material (PAM) was prepared from coal ash (CA, binder), rich­calcium (Ca) carbide slag (CS, active component) and iron salt (functional reagent) by optimizing materials ratios and roasting conditions. PAM prepared under optimal conditions (Fe/CC-2opt) had good phosphate adsorption efficiency. Notably, Fe/CC-2opt not only ensured that the effluent met Environmental Quality Standards for Surface Water (pH = 6.0-9.0), but also facilitated the formation of brushite instead of hydroxyapatite due to FeSO4 addition. Compared with hydroxyapatite, brushite had greater potential application value as fertilizer due to its solubility and high P/Ca ratio. The possible mechanisms of phosphate adsorption by PAM included surface precipitation, surface complexation, electrostatic adsorption and release of Ca2+/OH-. Preparation cost of PAM was 80 US$/ton, and treatment cost was 0.07 US$/g P. Regeneration efficiency of PAM was still above 80 % after five cycles. The design idea and result of this study provide theoretical basis and technical support for the preparation of PAM with low cost, commercial production and great adsorption capacity.

The potential of Lycium barbarum miR166a in kidney cancer treatment.

Predator species of animal can absorb plant microRNA that can regulate target gene expression and physiological function across species. The herb Lycium barbarum, a traditional Chinese medicine, has a wide range of antitumor effects. However, there are no reports on the effects of microRNA derived from it on the cross-border regulation of renal cell carcinoma (RCC). We performed in vitro and in vivo experiments to explore the role and mechanism of the L. barbarum-derived microRNA miR166a (Lb-miR166a) in cross-border regulation of RCC. Our mRNA sequencing analysis showed that Lb-miR166a regulates the expression of various genes in tumor cells, including 1232 upregulated genes and 581 downregulated genes, which were enriched to 1094 Gene Ontology entries and 43 Kyoto Encyclopedia of Genes and Genomes pathways. In vitro cell experiments confirmed that Lb-miR166a can inhibit the proliferation of RCC cells, promote the apoptosis of tumor cells, and inhibit the invasion and metastasis of tumor cells by regulating the expression of related genes. Furthermore, our in vivo tumor-bearing experiment showed that subcutaneous tumor formation volume decreased in Lb-miR166a mice, along with the number of liver metastases. This study elucidates the role and mechanism of Lb-miR166a in RCC treatment (Fig. 1). Our results further mechanistically confirm the antitumor properties of L. barbarum. Our study may contribute to the clinical development of a targeted drug for RCC treatment.

A brief review and case report of urothelial carcinoma and metachronous leiomyosarcoma of the bladder at the same anatomic region.

One patient with bladder leiomyosarcoma and urothelial carcinoma is very rare. Only 10 cases have been reported in the literature. A 70-year-old patient was admitted due to bladder tumor. Two TURBTs were performed confirming the patient was free of tumor, and pathology reported low-grade urothelial carcinoma. Three years later, a tumor was also found on the right anterolateral wall of urinary bladder and was diagnosed as leiomyosarcoma by pathological examination. Radical cystectomy was performed. With 45 months follow-up, the patient has no recurrence. Two malignancies in the same anatomic region at different time has never been reported to date.

Active targeted therapy for metastatic collecting duct carcinoma of the kidney: a case report and review of the literature.

Collecting duct carcinoma (CDC) is a rare and aggressive renal cell carcinoma (RCC) with extremely poor prognosis, which has been shown to have a poor response to several kinds of systemic therapy. Targeted agents have greatly changed the therapeutic landscape in advanced RCC. Nonetheless, patients with CDC are always excluded from the prospective trials with targeted therapies due to its rarity. We present a case of metastatic CDC that responded favorably to the multiple tyrosine kinase inhibitor, sorafenib, achieving a partial response in both lungs and retroperitoneal lymph nodes metastases. We also reviewed the limited number of reports of metastatic CDC treated with targeted agents and found that 33.33 % (4/12) of patients had favorable clinical activity. These suggest that targeted therapy should be considered for the treatment of metastatic CDC and its prospective evaluation is encouraged.